News | January 03, 2026
Cupid reports record Q3, eyes GCC expansion with Saudi FMCG facility
Cupid is strengthening its footprint in the GCC region, focusing on supply responsiveness and market proximity
Cupid is strengthening its footprint in the GCC region, focusing on supply responsiveness and market proximity
The resubmission of BLA for MOLBREEVI names Fujifilm as the drug substance manufacturer
The trials did not show a statistically significant reduction in annualized clinical fracture rates compared to placebo or bisphosphonates
It performs white blood cell differential counts and quantifies red blood cell and platelet morphology,
ICC is a highly aggressive liver cancer arising from the intrahepatic biliary epithelium
Experts warn that illegal products may be fake, contaminated, incorrectly dosed, or contain powerful unlisted ingredients
The applications aim to launch Phase Ib/II trials for relapsed/refractory multiple myeloma and primary plasma cell leukemia, respectively
The approval follows results from the DESTINY-Breast06 phase 3 trial, which showed ENHERTU significantly extended progression-free survival compared to chemotherapy
Singlera and Pure Medical will team up with local universities, hospital networks, and national healthcare systems across Western Europe for research studies
The cancellation underscores the regulator’s strict stance against misleading cosmetic claims
Subscribe To Our Newsletter & Stay Updated
